Cellectis S.A. American Depositary Shares — Chart, Price & News (NASDAQ:CLLS)

Open full chart

Financials

Overview Rapor Statistics

Quarterly Annual

Market Capitalization 281.98 M
Employee 229
Founded 1999
CEO André Choulika
Website www.cellectis.com
Headquarter France
FIGI BBG0084L1XN2
Industry Technology

Total revenue

Net income

Total debt

Free cash flow

Cash & equivalents

281.98 M Market capitalization

Cellectis S.A. - American Depositary Shares

Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.

Haberler

Cellectis hissesi alojenik platform nedeniyle outperform’da tutuldu

Citizens, Cellectis hissesi için hedef fiyatı korudu

Cellectis 4Ç 2025 beklentilerini aştı, hisse yükseldi

Cellectis kazancı $0,10 ile beklentilere göre daha iyi, kâr ise beklentilere göre yüksek

Jefferies, Cellectis hissesi için alım tavsiyesi ile takibe başladı

Jefferies assumes coverage on Cellectis stock with Buy rating

This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Brunswick (NYSE:BC), Cellectis (NASDAQ:CLLS)

Clear Street, CAR-T potansiyeli nedeniyle Cellectis hissesini Al tavsiyesiyle başlattı

Clear Street initiates Cellectis stock with Buy rating on CAR-T potential

Cellectis: Showcasing Encouraging Data, But Still Early To Make A Run Like This (CLLS)

Allogene Arbitration Victory Pressures Cellectis Shares Tuesday - Allogene Therapeutics (NASDAQ:ALLO), Cellectis (NASDAQ:CLLS)

Lightwave Logic, Kyverna Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Argo Blockchain (NASDAQ:ARBK), Ascent Solar Technologies (NASDAQ:ASTI)